Lantheus (LNTH) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lantheus (LNTH) has outperformed Myriad Genetics (MYGN) over the past year, gaining 82.9% versus a loss of 26.0%. Over five years, LNTH leads with a +266.1% price change compared with -79.5% for MYGN. Lantheus is the larger company by market cap ($6.68 billion vs $523.7 million), about 12.7 times the size.
Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -44.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | MYGN |
|---|---|---|
| Share price | $102.10 | $5.46 |
| Market cap | $6.68B | $523.74M |
| 1-day change | 0.00% | -1.44% |
| YTD return | +53.42% | -11.22% |
| 1-year return | +82.91% | -26.02% |
| 5-year return | +266.08% | -79.48% |
| P/E ratio (TTM) | 25.40 | — |
| Forward P/E | 15.34 | — |
| EPS (TTM) | $4.02 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | $824.50M |
| Revenue growth (YoY) | +0.50% | -1.56% |
| Net income (latest FY) | $233.56M | $-365.90M |
| Gross margin | 61.10% | 69.93% |
| Operating margin | 20.16% | -46.96% |
| Net margin | 15.15% | -44.38% |
| 52-week high | $111.86 | $8.09 |
| 52-week low | $54.94 | $2.74 |
| Distance from 52-week high | -8.73% | -32.51% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +3.81% | +8.06% |
| Average volume | 1.02M | 2.26M |
| Shares outstanding | 65.40M | 95.92M |
| Employees | 1,193 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 12.7 times larger than Myriad Genetics by market value ($6.68B vs $523.74M).
- LNTH has outperformed MYGN by 108.9 percentage points over the past year.
- Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -44.4 cents for Myriad Genetics.
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
LNTH vs MYGN FAQ
Which is bigger, Lantheus or Myriad Genetics?
Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $523.74M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, LNTH or MYGN?
LNTH returned +82.91% over the past 12 months, compared with -26.02% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and Myriad Genetics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.